Literature DB >> 15300582

Lack of immunological or molecular evidence for a role of mouse mammary tumor retrovirus in primary biliary cirrhosis.

Carlo Selmi1, Susan R Ross, Aftab A Ansari, Pietro Invernizzi, Mauro Podda, Ross L Coppel, M Eric Gershwin.   

Abstract

BACKGROUND & AIMS: Recent observations, including a pilot clinical trial, have suggested that a human mouse mammary tumor virus (MMTV) causes primary biliary cirrhosis (PBC). We attempted to confirm such data.
METHODS: We obtained sera from 101 patients (53 with PBC and 48 controls), fixed liver sections from 10 patients (8 PBC and 2 controls), fresh liver specimens (6 PBC and 6 controls), and fresh peripheral blood lymphocytes (PBLs) (10 PBC and 10 controls). We studied sera for reactivities against 3 different strains of MMTV virions, MMTV(C3H), MMTV(FM), and MMTV(LA), including goat polyclonal antibodies against MMTV virions, gp52, and p27 as positive controls. We stained liver specimens using polyclonal antibodies against MMTV and gp52 and further examined tissue samples and PBLs for specific MMTV genome sequences.
RESULTS: By Western blot analysis, no detectable reactivity in any of the PBC sera against any of the 3 MMTV strains or MMTV gp52 or p27 was observed. However, viral proteins were recognized by our control positive polyclonal antibodies. We note that 13%-60% of PBC sera presented low reactivity against 2 proteins of approximately 57 and 74 kilodaltons. Such reactivity is related to the trace amounts of mitochondrial antigens in the virus preparations derived from murine mammary tumor tissue. No detectable immunohistochemical or molecular evidence for MMTV was found in the liver specimens or PBLs.
CONCLUSIONS: We were unable to recapitulate the data on this specific retroviral etiology of PBC and suggest that such data could be the result of contamination.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15300582     DOI: 10.1053/j.gastro.2004.05.033

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  31 in total

Review 1.  Pathogenesis of primary biliary cirrhosis.

Authors:  David E J Jones
Journal:  Gut       Date:  2007-07-19       Impact factor: 23.059

2.  Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis.

Authors:  Ellina Lytvyak; Ishwar Hosamani; Aldo J Montano-Loza; Lynora Saxinger; Andrew L Mason
Journal:  Can Liver J       Date:  2019-01-09

3.  Etiopathogenesis of primary biliary cirrhosis: an overview of recent developments.

Authors:  Palak J Trivedi; Sue Cullen
Journal:  Hepatol Int       Date:  2012-03-20       Impact factor: 6.047

Review 4.  Combination antiretroviral studies for patients with primary biliary cirrhosis.

Authors:  Ellina Lytvyak; Aldo J Montano-Loza; Andrew L Mason
Journal:  World J Gastroenterol       Date:  2016-01-07       Impact factor: 5.742

Review 5.  Pathogen infections and primary biliary cholangitis.

Authors:  A Tanaka; P S C Leung; M E Gershwin
Journal:  Clin Exp Immunol       Date:  2018-09-17       Impact factor: 4.330

Review 6.  Update on primary biliary cirrhosis.

Authors:  Pietro Invernizzi; Carlo Selmi; M Eric Gershwin
Journal:  Dig Liver Dis       Date:  2010-03-31       Impact factor: 4.088

Review 7.  Experimental evidence on the immunopathogenesis of primary biliary cirrhosis.

Authors:  Carlo Selmi; Francesca Meda; Anaid Kasangian; Pietro Invernizzi; Zhigang Tian; Zhexiong Lian; Mauro Podda; M Eric Gershwin
Journal:  Cell Mol Immunol       Date:  2009-12-23       Impact factor: 11.530

8.  Quality of life and everyday activities in patients with primary biliary cirrhosis.

Authors:  Carlo Selmi; M Eric Gershwin; Keith D Lindor; Howard J Worman; Ellen B Gold; Mitchell Watnik; Jessica Utts; Pietro Invernizzi; Marshall M Kaplan; John M Vierling; Christopher L Bowlus; Marina G Silveira; Ilaria Bossi
Journal:  Hepatology       Date:  2007-12       Impact factor: 17.425

Review 9.  Bacteria and primary biliary cirrhosis.

Authors:  Dimitrios P Bogdanos; Diego Vergani
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

Review 10.  Primary biliary cirrhosis.

Authors:  Simon Hohenester; Ronald P J Oude-Elferink; Ulrich Beuers
Journal:  Semin Immunopathol       Date:  2009-07-15       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.